The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration

Launched by THE FIRST HOSPITAL OF JILIN UNIVERSITY · May 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called nafamostat mesylate on patients who have sepsis-induced coagulopathy (SIC) and are undergoing a treatment called hemofiltration. Sepsis is a severe infection that can cause problems with blood clotting, and SIC can lead to serious complications, including organ failure. The trial aims to determine whether nafamostat mesylate can help improve survival rates for these patients during their blood purification process while minimizing the risk of bleeding.

To participate in this study, individuals must be adults aged 18 and older who are diagnosed with SIC and are receiving hemofiltration. However, certain people, such as those under 18, pregnant or breastfeeding women, and those with specific bleeding risks or severe liver conditions, cannot join the trial. Participants will receive careful monitoring throughout the study to assess the safety and effectiveness of nafamostat mesylate. This trial is important because it could help improve treatment options for critically ill patients with SIC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (Age ≥ 18 years);
• • Patients with SIC Undergoing Hemofiltration.
• Exclusion Criteria:
• • Individuals under the age of 18, pregnant women, and breastfeeding mothers;
• • Patients with a history of high sensitivity to nafamostat mesylate (those who have experienced significant bleeding complications from previous use of nafamostat mesylate);
• • Fibrinogen \< 1.5 g/L;
• * Patients with bleeding or high risk of bleeding:
• • Those in the acute phase of trauma or with active bleeding (e.g., flail chest, obvious contusions of the lungs, liver, spleen, retroperitoneal bleeding, pelvic fractures, etc.); Those with a history of severe head trauma, intracranial surgery, stroke, cerebral aneurysm, or arteriovenous malformation within one month prior to enrollment; Those with a history of congenital bleeding disorders: such as hemophilia; Those with underlying fulminant hepatitis, decompensated cirrhosis, or other severe liver diseases.